Barclays Maintains Equal-Weight on Definitive Healthcare, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Saket Kalia maintains an Equal-Weight rating on Definitive Healthcare (NASDAQ:DH) but lowers the price target from $7 to $6.
July 31, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Saket Kalia maintains an Equal-Weight rating on Definitive Healthcare but lowers the price target from $7 to $6.
The lowered price target from $7 to $6 by Barclays suggests a less optimistic outlook for Definitive Healthcare, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100